close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

NCPA Testifies Before House Small Business Committee

ALEXANDRIA, Va., Dec. 6 /PRNewswire-USNewswire/ -- Charles Sewell, National Community Pharmacists Association (NCPA) senior vice president, Government Affairs, testified today before the U.S. House Small Business Committee. The hearing focused on strengthening the Regulatory Flexibility Act (RFA), which requires government agencies to examine and report on the impact of new regulations upon small businesses when they issue proposed rules. Sewell supported the need for a legislative fix after witnessing the Centers for Medicare & Medicaid Services' (CMS) failure to explore the ramifications its Medicaid generic prescription drug reimbursement regulations will have on the 23,000 small business independent pharmacies that NCPA represents.

"CMS' half-hearted attempt to follow the Regulatory Flexibility Act is going to spawn a financial crisis for independent pharmacies and a health crisis for their patients," said Sewell. "Simply put, CMS was derelict in its duty by not conducting a thorough economic study of its proposed or final regulations for Medicaid generic drug reimbursement. Putting more teeth into this law will ensure small businesses are not an afterthought when creating regulations."

CMS' Medicaid generic drug reimbursement regulation is based on its Average Manufacturer Price (AMP) definition that does not accurately reflect retail acquisition costs. In fact, a Government Accountability Office (GAO) study determined that independent pharmacies would average reimbursements 36 percent below their cost under CMS' regulation. CMS did not conduct a similar study.

CMS will fully implement its AMP rule on January 30, 2008. At that time independent pharmacies, which are often located in underserved rural and urban communities, will be forced to make the business decision to either limit or drop out of Medicaid, or even go out of business. Their patients, with their access to prescription drug services curtailed, will have to explore other, more expensive health care options such as emergency room visits.

NCPA is pursuing a variety of legal and legislative remedies to delay or change CMS' AMP regulation. In Sewell's testimony he offered several recommendations for how the RFA could be improved in the future for other small businesses.

"An agency should not issue a final regulation unless it specifically analyzes the significant impact that rule will have on small businesses," said Sewell. "Agencies would no longer be able to hide behind the excuse of having a lack of evidence. In order to proceed, they would have to find that there is no adverse impact. If studies exist showing the rule will significantly impact small businesses (defined as a loss of 3 percent or more of gross revenue), the agency cannot simply dismiss them and proceed with implementation, nor can the agency act if it has not found any relevant data. Finally, a mechanism would be in place for a person or entity to issue a regulatory challenge of any agency that releases a final rule that it believes violate the RFA."

If all of these recommendations are adopted, it is unlikely the situation currently jeopardizing patient access and confronting community pharmacies would have transpired.

To view Sewell's entire testimony go here: http://www.ncpanet.org/pdf/leg/amp_sba_committee_testimony.pdf

The National Community Pharmacists Association, founded in 1898, represents the nation's community pharmacists, including the owners of more than 23,000 pharmacies. The nation's independent pharmacies, independent pharmacy franchises, and independent chains dispense nearly half of the nation's retail prescription medicines. For more information go to www.ncpanet.org.

Source: National Community Pharmacists Association

CONTACT: John Norton of the National Community Pharmacists Association,
+1-703-683-8200, John.norton@ncpanet.org

Web Site: http://www.ncpanet.org/

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...